A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center

NCT05081440 | Unknown

• 1 other identifier: START-CHC
• Study Type: observational
• Target: 5,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

A multi-center, prospective, observational Study to describe the siTuation of blood lipid mAnagement among the population with hypeRtension and/or type 2 diabeTes in Community Health Center

Conditions

Lipoprotein Disorder

Outcome Measures

Primary Outcomes (1)

• primary outcome

  To evaluate the blood lipid levels and current status of drug treatment in patients with CHC hypertension and/or type 2 diabetes Describe the characteristics of blood lipid treatment in patients with CHC with hypertension and/or type 2 diabetes with LDL-C between 2.6 and 4.1 mmol/L

  2022.12.01

Secondary Outcomes (1)

• secondary outcome

  2022.12.01

Study Arms (1)

patients diagnosed with hypertension or diabetes

Age ≥18 years; Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for ≥ 3 months; The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

5000 patients with hypeRtension and/or type 2 diabeTes inCommunity Health Center

You may qualify if:

• The informed consent form (ICF) should be signed before conducting any research-related operations
• Age ≥18 years
• Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for ≥ 3 months
• The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded

You may not qualify if:

• Patients with well-diagnosed atherosclerotic cardiovascular disease (ASCVD) 2. Have received any form of lipid-lowering treatment within 4 weeks before the screening period 3. The patient is currently participating in any other clinical trial except this study

Sponsors & Collaborators

• Huashan Hospital: lead
• Pfizer: collaborator

Central Study Contacts

yong li

CONTACT

+86 13801753494; liyong606@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD, MD

Study Record Dates

• First Submitted: October 5, 2021
• First Posted: October 18, 2021
• Study Start: December 1, 2021
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: October 18, 2021

Record last verified: 2021-10